Holst JJ - Search Results

1

Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion.

Müssig K, Staiger H, Machicao F, Kirchhoff K, Guthoff M, Schäfer SA, Kantartzis K, Silbernagel G, Stefan N, Holst JJ, Gallwitz B, Häring HU, Fritsche A. Müssig K, et al. Among authors: holst jj. Diabetes. 2009 Jul;58(7):1715-20. doi: 10.2337/db08-1589. Epub 2009 Apr 14. Diabetes. 2009. PMID: 19366866 Free PMC article.

2

Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.

Gutniak MK, Linde B, Holst JJ, Efendić S. Gutniak MK, et al. Among authors: holst jj. Diabetes Care. 1994 Sep;17(9):1039-44. doi: 10.2337/diacare.17.9.1039. Diabetes Care. 1994. PMID: 7988303 Clinical Trial.

3

The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.

Toft-Nielson M, Madsbad S, Holst JJ. Toft-Nielson M, et al. Among authors: holst jj. Diabetes. 1996 May;45(5):552-6. doi: 10.2337/diab.45.5.552. Diabetes. 1996. PMID: 8621002

4

Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.

Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S. Gutniak MK, et al. Among authors: holst jj. Diabetes Care. 1996 Aug;19(8):857-63. doi: 10.2337/diacare.19.8.857. Diabetes Care. 1996. PMID: 8842604 Clinical Trial.

5

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB. Vaag AA, et al. Among authors: holst jj. Eur J Endocrinol. 1996 Oct;135(4):425-32. doi: 10.1530/eje.0.1350425. Eur J Endocrinol. 1996. PMID: 8921824

6

Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.

Pørksen N, Grøfte B, Nyholm B, Holst JJ, Pincus SM, Veldhuis JD, Schmitz O, Butler PC. Pørksen N, et al. Among authors: holst jj. Diabetes. 1998 Jan;47(1):45-9. doi: 10.2337/diab.47.1.45. Diabetes. 1998. PMID: 9421373 Clinical Trial.

7

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ. Toft-Nielsen MB, et al. Among authors: holst jj. Diabetes Care. 1999 Jul;22(7):1137-43. doi: 10.2337/diacare.22.7.1137. Diabetes Care. 1999. PMID: 10388979 Clinical Trial.

8

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Vilsbøll T, et al. Among authors: holst jj. Diabetes Care. 2000 Jun;23(6):807-12. doi: 10.2337/diacare.23.6.807. Diabetes Care. 2000. PMID: 10841001

9

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Vella A, et al. Among authors: holst jj. Diabetes. 2000 Apr;49(4):611-7. doi: 10.2337/diabetes.49.4.611. Diabetes. 2000. PMID: 10871199 Clinical Trial.

10

Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.

Henriksen JE, Levin K, Thye-Rønn P, Alford F, Hother-Nielsen O, Holst JJ, Beck-Nielsen H. Henriksen JE, et al. Among authors: holst jj. Diabetes. 2000 Jul;49(7):1209-18. doi: 10.2337/diabetes.49.7.1209. Diabetes. 2000. PMID: 10909980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,777 results

Search Page

Filters